Neurochase CED Device Platform
Neurological Diseases (Platform Validation)
Key Facts
About Neurochase
Neurochase is building a premier global platform for targeted CNS drug delivery, combining proprietary device technology with deep clinical expertise. The company's strategy is twofold: it offers high-value consultancy and training services for pre-clinical and clinical CNS delivery programs, and it is developing its own Convection Enhanced Delivery (CED) devices, bolstered by the strategic 2025 acquisition of Renishaw Neuro Solutions' Neuroinfuse™ system. With a planned clinical trial for its device platform in early 2026 and a team that has executed over 5,000 human catheter infusions, Neurochase is positioning itself as an essential enabler for the burgeoning field of neurological gene and cell therapies.
View full company profile